

**TABLE 405-2 CHARACTERISTICS OF CIRCULATING T<sub>4</sub> AND T<sub>3</sub>**

| Hormone Property                                 | T <sub>4</sub>           | T <sub>3</sub>          |
|--|--------------------------|-------------------------|
| Serum concentrations                             |                          |                         |
| Total hormone                                    | 8 µg/dL                  | 0.14 µg/dL              |
| Fraction of total hormone in the unbound form    | 0.02%                    | 0.3%                    |
| Unbound (free) hormone                           | 21 × 10 <sup>-12</sup> M | 6 × 10 <sup>-12</sup> M |
| Serum half-life                                  | 7 d                      | 2 d                     |
| Fraction directly from the thyroid               | 100%                     | 20%                     |
| Production rate, including peripheral conversion | 90 µg/d                  | 32 µg/d                 |
| Intracellular hormone fraction                   | ~20%                     | ~70%                    |
| Relative metabolic potency                       | 0.3                      | 1                       |
| Receptor binding                                 | 10 <sup>-10</sup> M      | 10 <sup>-11</sup> M     |

When the effects of the various binding proteins are combined, approximately 99.98% of T<sub>4</sub> and 99.7% of T<sub>3</sub> are protein-bound. Because T<sub>3</sub> is less tightly bound than T<sub>4</sub>, the fraction of unbound T<sub>3</sub> is greater than unbound T<sub>4</sub>, but there is less unbound T<sub>3</sub> in the circulation because it is produced in smaller amounts and cleared more rapidly than T<sub>4</sub>. The unbound or “free” concentrations of the hormones are ~2 × 10<sup>-11</sup> M for T<sub>4</sub> and ~6 × 10<sup>-12</sup> M for T<sub>3</sub>, which roughly correspond to the thyroid hormone receptor binding constants for these hormones (see below). The unbound hormone is thought to be biologically available to tissues. Nonetheless, the homeostatic mechanisms that regulate the thyroid axis are directed toward maintenance of normal concentrations of unbound hormones.

**Abnormalities of Thyroid Hormone Binding Proteins** A number of inherited and acquired abnormalities affect thyroid hormone binding proteins. X-linked TBG deficiency is associated with very low levels of total T<sub>4</sub> and T<sub>3</sub>. However, because unbound hormone levels are normal, patients are euthyroid and TSH levels are normal. It is important to recognize this disorder to avoid efforts to normalize total T<sub>4</sub> levels, because this leads to thyrotoxicosis and is futile because of rapid hormone clearance in the absence of TBG. TBG levels are elevated by estrogen, which increases sialylation and delays TBG clearance. Consequently, in women who are pregnant or taking estrogen-containing contraceptives, elevated TBG increases total T<sub>4</sub> and T<sub>3</sub> levels; however, unbound T<sub>4</sub> and T<sub>3</sub> levels are normal. These features are part of the explanation for why women with hypothyroidism require increased amounts of L-thyroxine replacement as TBG levels are increased by pregnancy or estrogen treatment. Mutations in TBG, TTR, and albumin may increase the binding affinity for T<sub>4</sub> and/or T<sub>3</sub> and cause disorders known as *euthyroid hyperthyroxinemia* or *familial dysalbuminemic hyperthyroxinemia* (FDH) (Table 405-3). These disorders result in increased total T<sub>4</sub> and/or T<sub>3</sub>, but unbound hormone levels are normal. The familial nature of the disorders, and the fact that TSH levels are normal rather than suppressed, should suggest this diagnosis. Unbound hormone levels (ideally measured by dialysis) are normal in FDH. The diagnosis can be confirmed by using tests that measure the affinities of radiolabeled hormone binding to specific transport proteins or by performing DNA sequence analyses of the abnormal transport protein genes.

Certain medications, such as salicylates and salsalate, can displace thyroid hormones from circulating binding proteins. Although these drugs transiently perturb the thyroid axis by increasing free thyroid hormone levels, TSH is suppressed

until a new steady state is reached, thereby restoring euthyroidism. Circulating factors associated with acute illness may also displace thyroid hormone from binding proteins (see “Sick Euthyroid Syndrome,” below).

**Deiodinases** T<sub>4</sub> may be thought of as a precursor for the more potent T<sub>3</sub>. T<sub>4</sub> is converted to T<sub>3</sub> by the deiodinase enzymes (Fig. 405-1). Type I deiodinase, which is located primarily in thyroid, liver, and kidneys, has a relatively low affinity for T<sub>4</sub>. Type II deiodinase has a higher affinity for T<sub>4</sub> and is found primarily in the pituitary gland, brain, brown fat, and thyroid gland. Expression of type II deiodinase allows it to regulate T<sub>3</sub> concentrations locally, a property that may be important in the context of levothyroxine (T<sub>4</sub>) replacement. Type II deiodinase is also regulated by thyroid hormone; hypothyroidism induces the enzyme, resulting in enhanced T<sub>4</sub> → T<sub>3</sub> conversion in tissues such as brain and pituitary. T<sub>4</sub> → T<sub>3</sub> conversion is impaired by fasting, systemic illness or acute trauma, oral contrast agents, and a variety of medications (e.g., propylthiouracil, propranolol, amiodarone, glucocorticoids). Type III deiodinase inactivates T<sub>4</sub> and T<sub>3</sub> and is the most important source of reverse T<sub>3</sub> (rT<sub>3</sub>), including in the sick euthyroid syndrome. This enzyme is expressed in the human placenta but is not active in healthy individuals. In the sick euthyroid syndrome, especially with hypoperfusion, the type III deiodinase is activated in muscle and liver. Massive hemangiomas that express type III deiodinase are a rare cause of hypothyroidism in infants.

### THYROID HORMONE ACTION

**Thyroid Hormone Transport** Circulating thyroid hormones enter cells by passive diffusion and via specific transporters such as the monocarboxylate 8 transporter (MCT8), MCT10, and organic anion-transporting polypeptide 1C1. Mutations in the *MCT8* gene have been identified in patients with X-linked psychomotor retardation and thyroid function abnormalities (low T<sub>4</sub>, high T<sub>3</sub>, and high TSH). After entering cells, thyroid hormones act primarily through nuclear receptors, although they also have nongenomic actions through stimulating mitochondrial enzymatic responses and may act directly on blood vessels and the heart through integrin receptors.

**Nuclear Thyroid Hormone Receptors** Thyroid hormones bind with high affinity to nuclear *thyroid hormone receptors* (TRs) α and β. Both TRα and TRβ are expressed in most tissues, but their relative expression levels vary

**TABLE 405-3 CONDITIONS ASSOCIATED WITH EUTHYROID HYPERTHYROXINEMIA**

| Disorder   | Cause   | Transmission | Characteristics   |
|--|---|--------------|---|
| Familial dysalbuminemic hyperthyroxinemia (FDH)              | Albumin mutations, usually R218H                        | AD           | Increased T <sub>4</sub><br>Normal unbound T <sub>4</sub><br>Rarely increased T <sub>3</sub>                        |
| TBG  |   |              |   |
| Familial excess  | Increased TBG production                                | XL           | Increased total T <sub>4</sub> , T <sub>3</sub><br>Normal unbound T <sub>4</sub> , T <sub>3</sub>                   |
| Acquired excess  | Medications (estrogen), pregnancy, cirrhosis, hepatitis | Acquired     | Increased total T <sub>4</sub> , T <sub>3</sub><br>Normal unbound T <sub>4</sub> , T <sub>3</sub>                   |
| Transthyretin <sup>a</sup>                                   |   |              |   |
| Excess   | Islet tumors  | Acquired     | Usually normal T <sub>4</sub> , T <sub>3</sub>  |
| Mutations  | Increased affinity for T <sub>4</sub> or T <sub>3</sub> | AD           | Increased total T <sub>4</sub> , T <sub>3</sub><br>Normal unbound T <sub>4</sub> , T <sub>3</sub>                   |
| Medications: propranolol, ipodate, iopanoic acid, amiodarone | Decreased T <sub>4</sub> → T <sub>3</sub> conversion    | Acquired     | Increased T <sub>4</sub><br>Decreased T <sub>3</sub><br>Normal or increased TSH                                     |
| Resistance to thyroid hormone (RTH)                          | Thyroid hormone receptor β mutations                    | AD           | Increased unbound T <sub>4</sub> , T <sub>3</sub><br>Normal or increased TSH<br>Some patients clinically thyrotoxic |

<sup>a</sup>Also known as thyroxine-binding prealbumin (TBPA).

**Abbreviations:** AD, autosomal dominant; TBG, thyroxine-binding globulin; TSH, thyroid-stimulating hormone; XL, X-linked.